Related Experiment Videos
Foscarnet decreases human immunodeficiency virus RNA
L Kaiser1, L Perrin, B Hirschel
1Division of Infectious Diseases, University Hospital, Geneva, Switzerland.
The Journal of Infectious Diseases
|July 1, 1995
Summary
Foscarnet significantly reduces human immunodeficiency virus (HIV) RNA levels in patients, demonstrating its potent antiretroviral activity. This antiviral drug effectively inhibits HIV replication, offering a new therapeutic option.
Area of Science:
- Virology
- Immunology
- Pharmacology
Background:
- Foscarnet is known to inhibit human immunodeficiency virus (HIV) replication in vitro.
- It also decreases p24 antigenemia in patients with cytomegalovirus (CMV) retinitis.
Purpose of the Study:
- To evaluate the effect of foscarnet on HIV replication in patients.
- To quantify changes in HIV RNA levels before and during foscarnet therapy.
Main Methods:
- Seventeen patients receiving foscarnet for CMV retinitis, CMV encephalitis, or zoster were included.
- HIV RNA levels were measured before and during foscarnet treatment.
Main Results:
- A significant decrease in HIV RNA was observed in 16 out of 17 patients.
- Mean HIV RNA decreased from 5.82 log RNA/mL to 5.30 log RNA/mL (P < .001).
- A significant decrease in p24 antigen was noted in patients with detectable levels at baseline (P = .017).
Conclusions:
- Foscarnet demonstrates potent antiretroviral activity by significantly reducing HIV RNA levels.
- These findings support foscarnet as an effective treatment for HIV replication.